CD36 Enrichment in HER2-Positive Mesenchymal Stem Cells Drives Therapy Refractoriness in Breast Cancer

Scientists elucidated whether enhanced CD36 in mesenchymal HER2 + CSCs was directly involved in anti-HER2 treatment refractoriness in HER2 + breast cancer and to design future metabolism-based approaches targeting both fatty acid reprogramming and the “root” of cancer.